Participated · Series B · Aug 2026

Mironid develops first-in-class small-molecule LoAc® drug candidates that directly target abnormally high kidney cAMP levels that drive cyst formation in ADPKD. Its lead programmes are focused on treating Autosomal Dominant Polycystic Kidney Disease, a hereditary disorder affecting over 12 million people worldwide with about 50% of patients developing kidney failure by age 60. The company was founded through collaboration between the University of Strathclyde and Heriot-Watt University and is led by CEO Neil Wilkie. Mironid has progressed a series of drug-development programmes targeting specific enzymes to generate differentiated therapies for diseases with high unmet need. The recently closed £34m Series B, which includes an £8.4m equity investment from SNIB and participation from Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde, will fund clinical development and advancement of its lead candidate.

Led · Series A · Jun 2026

Bionyra is advancing a pipeline of next-generation mono- and multispecific antibodies engineered with half-life extension to target immune pathways in diseases with high unmet need. Lead programs include BYN-002, a TL1A monoclonal antibody in a fully enrolled Phase 1 in healthy subjects; BYN-003, a TL1A*IL-23p19 bispecific that entered Phase 1 in April; and BYN-001, an IL-25 monoclonal antibody in IND-stage for atopic dermatitis and type 2 inflammation. The company holds exclusive global rights to these assets outside Greater China through licenses from TrueLab Biopharmaceutical and NovaRock Biotherapeutics, and is progressing additional preclinical assets. Bionyra was co-founded and seed financed by Sofinnova Partners and is led by CEO Frédéric Marrache, a former Sanofi R&D executive with experience in immunology and inflammation. The company plans to use its Series A proceeds to advance clinical development and rapidly generate clinical validation in dermatology and inflammatory bowel disease.

Led · Seed · Jun 2026

Ingenix was founded in 2023 and is headquartered in Warsaw. The company develops the Biological Reasoning Engine, an AI system built on a Modality Fusion architecture that integrates best-in-class models across modalities and biological scales and reasons across their representations. Outputs from the Engine include a reasoning trace that lays out mechanism, evidence, and caveats alongside conclusions for translational and clinical R&D decision-making. Ingenix said the Engine produced candidate ADC payload combinations for an oncology biotech in minutes, including novel hypotheses and several actionable candidates. The company plans to broaden work with pharma and biotech partners through a newly launched Qualified Access Program. Financially, Ingenix raised a €13m seed-extension round led by Sofinnova Partners with participation from Inovo VC and OTB VC to scale the Engine and expand partner engagements.

Led · Equity · May 2026

P2 Science develops proprietary, nature-inspired chemical processes to produce renewable specialty ingredients with a focus on performance and sustainability at scale. The company has launched beauty ingredients including Citrolatum® P, a 1:1 plant-based petrolatum replacement, and CitroComplex® Nourish, a natural oil blend for skin and hair, and entered a strategic partnership with Algenesis to develop 100% biobased, biodegradable polyurethanes. P2 has been recognized by Fast Company in 2025 and 2026 and was selected for L'Oréal's L'AcceleratOR sustainable innovation accelerator. It recently received $2.8 million in non-dilutive ARPA-E funding to accelerate catalyst innovation via AI-enhanced autonomous labs. The company plans to use its new equity financing to scale commercial production in beauty and expand its platform into adjacent markets such as aroma technologies, performance polymers, home care, coatings, and crop care. P2 was co-founded by Professor Paul Anastas and Dr. Patrick Foley at Yale's Center for Green Chemistry and Green Engineering and is based in Woodbridge, Connecticut.

Participated · Series D · May 2026

CellCentric is a privately held, clinical-stage biotech company developing inobrodib, an orally bioavailable p300/CBP inhibitor. The lead program is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, and the company is enrolling a Phase 2 DOMMINO-1 study in the UK and US. CellCentric plans to initiate the global Phase 3 DOMMINO-2 trial in the second half of 2026. The company holds an IP portfolio and has clinical collaborations and strategic partnerships that provide external validation. Led by CEO Will West, CellCentric is based in Cambridge, UK, and maintains an additional office in Boston, MA. The article did not disclose revenue or other operating metrics.